natgillin/translations-raw huggingface dataset:
An antibody or antigen-binding fragment of an antibody according to any one of claims 1 to 4 for use in a method of attenuating or inhibiting a NGF-mediated disease or condition in a human selected from inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, gout joint pain, post-herpetic neuralgia, pain resulting from burns, cancer pain, osteoarthritis or rheumatoid arthritis pain, sciatica, pain associated with sickle cell crises, or post-herpetic neuralgia. 
Antitijelo ili fragment koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time, da je namijenjen za upotrebu u postupku za smanjivanje ili inhibiranje stanja ili bolesti posredovanih NGF-om kod čovjeka odabranih između upalne boli, postoperativne boli uslijed operativnih rezova, neuropatske boli, boli uzrokovane lomom, kostobolje u zglobovima, post-herpetične neuralgije, boli uzrokovane opeklinama, boli uzrokovane karcinomom, boli uzrokovane osteoartritisom i reumatoidnim artritisom, išijas, bol povezanu s krizom srpastih stanica, ili post-herpetičke neuralgije.
Compound of formula (VI) may be synthesized according to the method described in J. Med. 
Spoj formule (VI) može sc sintetizirati postupkom opisanim u J. Med.
ID. NO: 29. A composition for the removal of biofilm generated by Staphylococcus aureus containing lytic protein derived from the bacteriophage capable of killing Staphylococcus aureus specifically and effective in destroying biofilm formed by Staphylococcus aureus as an active ingredient, wherein the lytic protein derived from the bacteriophage has the amino acid sequence represented by SEQ. 
Sastav za uklanjanje biofilma stvorenog od Staphylococcus aureusa kao aktivni sastojak sadrži litički protein izveden iz bakteriofaga sposobnog za ubijanje Staphylococcus aureusa specifično i učinkovito u uništavanju biofilma stvorenog od Staphylococcus aureusa, pri čemu litički protein izveden iz bakteriofaga ima aminokiselinski slijed predstavljen SEQ ID NO: 28 ili SEQ ID NO: 31.
The solution according to anyone of claims 1 to 3, wherein the propranolol or pharmaceutically acceptable salts thereof is present in an amount of from 0.01 to 5% w/V, for example 0.01 to 1% w/V. 
Otopina suklano bilo kojem patentnih zahtjevu od 1 do 3, pri čemu je propranolol ili njegove farmaceutski prihvatljive soli u količini od 0.01 do 5% tež/vol, primjerice 0.01 do 1% tež/vol.
As an alternative to the pellet shape, the chewing gum according to the invention can be configured so that said first region and said second region are arranged in overlapping, alternating layers. 
6. Žvakaća guma prema jednom ili više od patentnih zahtjeva 1-5, naznačeno time da je cink sadržan u rečenoj prvoj regiji.
The process of claim 7 wherein expression of the nucleic acid begins while in the active growth phase of the culturing step. 
Postupak prema zahtjevu 4, naznačen time, da ekspresija nukleinske kiseline počinje dok traje faza aktivnog Tasta u koraku kultiviranja.
A method for preparing a compound of formula (I): wherein is a member selected from the group consisting of: 
"Metoda za pripremanje spoja formule (I): naznačena time, što jo R! član odabran iz grupe koja se sastoji od: 2
A tool changing device (10) for a cutting head of a machine for cutting flat glass sheets, characterized in that it comprises, so that they can slide in a parallel arrangement with means for sliding on a bridge (11) that supports a cutting head (12), 
HR P20140440 T1 PATENTNI ZAHTJEVI Uređaj za izmjenu alata (10) glave za rezanje stroja za rezanje ravnih ploča stakla, naznačen time da sadrži, kako bi mogli kliziti paralelno sa sredstvima za klizanje na most (11) koji podupire glavu za rezanje (12),
The method of claim 8, wherein the at least one physiologically acceptable excipient is propylene glycol, cetylic alcohol, glyceryl monostearate, liquid paraffin, or a combination of any of the foregoing. 
Farmaceutski pripravak koji sadrži korteksolon-17a-propionat u kristalnom obliku I u skladu s bilo kojim od patentnih zahtjeva 17 do 18, naznačen time što dodatno sadrži najmanje jednu fiziološki prihvatljivu pomoćnu tvar.
The present invention also provides a method for treating hereditary non-spherocytic hemolytic anemia comprising administering to a subject in need thereof a therapeutically effective amount of (1) a compound disclosed herein or a pharmaceutically acceptable salt thereof; (2) a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Spoj za uporabu u liječenju hemolitičke anemije koje sadrži primjenu na subjekta kod kojeg postoji potreba za tim terapeutski efikasne količine (1) spoja formule I ili njegove farmaceutski prihvatljive soli; ili (2) farmaceutski prihvatljive kompozicije koja sadrži spoj formule I ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivi nosač; pri čemu je formula I kao što je definirana u patentnom zahtjevu 1.
Floor panel according to claim 2 or 3, characterized in that said material part forms a connection between the lock-up body (14) and an attachment portion (50), wherein the lock-up body (14) and the attachment portion (50) consist of material which is less flexible than the aforementioned material part. 
Podni panel prema patentnom zahtjevu 2 ili 3, naznačen time što navedeni dio materijala čini vezu između elementa za blokiranje (14) 1 spojnog dijela (50), pri čemu se element za blokiranje (14) 1 spojni dio (50) sastoje od materijala koji je manje fleksibilan od prethodno navedenog dijela materijala.
regenerating, by the source eNB, the special data packet with the end marker to be sent to the target eNB through the X2 interface, wherein the special data packet to be sent to the target eNB does not contain user data, and the end marker in the special data packet to be sent to the target eNB is set in the header of the special data packet to be sent to the target eNB to indicate that the special data packet is the last data packet to be sent from the source eNB to the target eNB. 
LTE mreža prema zahtjevu 5, naznačena time da je SGW konfiguriran da generira poseban paket podataka i šalje poseban paket podataka prema izvorišnom eNB nakon što SGW provede komutaciju puta; i izvorišni eNB je konfiguriran da regenerira specijalni paket podataka sa završnom oznakom u skladu sa posebnim paketom podataka poslanim od SGW i šalje regenerirani posebni paket podataka prema ciljnom eNB, pri čemu regenerirani posebni paket podataka ne sadrži pakete korisničkih podataka i nosi broj PDCP sekvence slijedećeg paketa korisničkih podataka koji se treba poslati od izvornog eNB.
Statement 46. A metered dose inhaler according to any of statements 41 through 43, wherein the fine particle fraction is substantially maintained throughout emptying of the canister, after said canister is subjected to temperatures alternating between -5 °C and 40 °C every 6 hours for a period of six weeks. 
Inhalator za odmjerene doze u skladu s patentnim zahtjevom 15, naznačen time što se frakcija finih čestica uglavnom održava tijekom pražnjenja spremnika, nakon što se navedeni spremnik podvrgava temperaturama koje variraju između -5 *C 1 40 "C svakih 6 sati u periodu od šest tjedana.
inhibiting condensation of the vaporized gas, wherein inhibiting condensation of the vaporized gas comprises heating the vaporized gas; 
inhibiranje kondenzacije isparenog plina, pri čemu se inhibiranje kondenzacije isparenog plina sastoji od grijanja isparenog plina;
FIGS. 4 and 5 are schematic illustrations of an atomiser 11 according to the invention which comprises the microfluidic arrangements or nozzle arrangement 1 according to the first or second embodiment for atomising a fluid 12, particularly a highly effective drug or the like, in its untensioned state (FIG. 
Slike 4 i 5 prikazuju shematski atomizer 11 prema izumu koji obuhvaća mikrofluidne naprave ili napravu s mlaznicom 1 prema prvoj ili drugoj izvedbi za atomizaciju tekućine 12, posebno lijeka visoke učinkovitosti ili sličnog, u njegovom nenapregnutom stanju (slika 4) i u njegovom napregnutom stanju (slika 5).
The anti-IL-5 antibody for the use according to claim 10, wherein said the mean plasma concentration of said antibody is 46.9 ± 10.6 µg/mL and the AUC(0-inf) of said antibody is 1395 ± 348 µg×day/mL. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 8, naznačeno time što je navedena srednja koncentracija u plazmi navedenog protutijela 46,9 + 10,6 ug/ml, a AUC(o.<) za navedeno protutijelo je 1395 + 348 ugxdan/ml.
A medicinal cream as claimed in claims 1, 3, and 4 further comprising an antioxidant which is selected from a group comprising Butylated Hydroxy Anisole, Butylated Hydroxy Toluene and the like, or any combination thereof, and added in an amount from about 0.001 % (w/w) to 1% (w/w). 
Medicinska krema prema patentnim zahtjevima 1, 3 i 4, naznačena time, da nadalje sadrži antioksidans koji se odabire iz skupine koja sadrži butilirani hidroksianisol, butilirani hidroksitoluen 1 slične, ili bilo koju njihovu kombinaciju i dodaje u količini od oko 0,001% (tež.) do 1% (tež.).
sterile filling/blending two active ingredients, first active ingredient being ceftriaxone sodium and second ingredient being sulbactam sodium, 
(a) sterilno punjenje/miješanje dva aktivna sastojka, prvi aktivni sastojak je ceftriakson natrij, a drugi sastojak je sulbaktam natrij,
The method of claim 1, wherein the anti-sclerostin antibody is administered at about 2 mg/kg. 
Antitijelo za uporabu prema zahtjevu 1 ili 2, naznačeno time, da je količina Anti-sklerostin antitijela koja se primjenjuje oko 2 mg/kg.
Hydrolysis of Peak 1 to give Isomer C 20% aqueous sodium hydroxide solution (53 ml) was added to a stirred solution of Mosher's ester peak 1 (2.37 g, 4.43 mmol) in methanol (158 ml) and the mixture stirred at reflux for 150 minutes. 
Hidroliza Peak-a 1 da bi se dobio Izomer C (spoj izuma) 20%-tna vodena otopina natrij hidroksida (53 ml) se doda u miješanu otopinu Mosher-ovog estera peak-a 1 (2.37 g, 4.43 mmol) u metanolu (158 ml) i smjesa se miješa uz refluks tijekom 150 minuta.
An additive composition as claimed in any one of claims 1 to 5, wherein the additive composition does not comprise a 'nitrogen containing compound' nor 'an halide compound'. 
Sastav aditiva temeljem bilo kojeg od zahtjeva 1 do 5, naznačen time što sastav aditiva ne uključuje "spoj koji sadrži dušik" niti "spoj halida".
comparing the measured parameter value with a predetermined parameter value, and providing the amount of injected solution of calcium carbonate on the basis of the difference between the measured and the predetermined parameter value. 
€) uspoređivanje izmjerene parametarske vrijednosti s predodređenom parametarskom vrijednosti, te f) osiguravanje količine ubrizgane otopine koja je dobivena iz kalcijevog karbonata na temelju razlike između izmjerene i predodređene parametarske vrijednosti.
the medicament of the aforementioned (11), which is an agent for the prophylaxis or treatment of circulatory diseases; 
Lijek u skladu sa zahtjevom 9, naznačen time, da se koristi za profilaksu ili liječenje degenerativnih oboljenja živaca.
a lubricant. The subject invention provides a pharmaceutical tablet formulation (Formulation F) comprising per unit dosage form e.g. per tablet the following ingredients: 
L Farmaceutska formulacija tablete, naznačena time, da sadrži po jediničnom dozirnom obliku, na primjer po tableti, slijedeće sastojke:
monitoring and/or signaling a status of the active load and/or one or more parts of the electronic system by using said holding current. The method according to claim 13, comprising: 
praćenju i/ili signaliziranju (210) statusa aktivnog tereta (50) i/ili jednom ili više dijelova elektronskog sustava (1) upotrebom navedene struje držanja (Ig).
A compound of the following formula: in which 
Spoj slijedeće formule: gdje
The bag-in-container according to claim 1, wherein the at least one vent is in the shape of a wedge with the broad side at the level of the opening thereof and getting thinner as it penetrates deeper into the bag-in-container, until the inner and outer layers meet to form an interface. 
Posuda s vrećicom unutar nje prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da je barem jedan otvor (3) u obliku klina sa širokom stranom u ravnini s otvorom istoga te koji se sužava kako dublje ulazi u posudu, dok se unutrašnji (21) i vanjski (22) slojevi ne sastanu tako da oblikuju međuprostor (14).
The compound, or single stereoisomer or mixture of stereoisomers thereof, of Claim 6 where the cancer is breast cancer, colon cancer, rectal cancer, endometrial cancer, gastric carcinoma, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or thyroid carcinoma. 
Spoj, ili njegov pojedinačni stereoizomer ili smjesa stereoizomera, prema patentnom zahtjevu 50, naznačen time što je kancer – kancer dojke, kancer debelog crijeva, kancer rektuma, kancer endometrija, karcinom želudca, glioblastom, hepatostanični karcinom, sitnostanični kancer pluća, nesitnostanični kancer pluća, melanom, kancer jajnika, kancer grlića materice, kancer pankreasa, karcinom prostate, akutna mijelogena leukemija (AML), kronična mijelogena leukemija (CML) ili karcinom tireoidee.
taking a pipe 2 made of thermoplastic material having an end 20 heated to a plastically deformable state; 
- < uzimanja cijevi (2) izrađene od termoplastičnog materijala koja ima završetak (20) zagrijan do stanja plastične deformacije;
In a still further aspect, the present invention relates to a compound of formula I or a salt thereof, wherein R1 is selected from C1-6 alkyl (such as methyl), R3 is selected from C1-6 alkyl (such as methyl), and R6 is selected from halogen (such as F), and R2, R4—R5, and R7—R9 are all hydrogen. 
U još jednom aspektu ovaj izum se odnosi na spoj formule I ili njegovu sol, ako je R! odabran iz C,4 alkila (poput metila), R* je odabran iz C,. alkila (poput metila), a R" je odabran iz halogena (poput F), dok su R?, R*, R? i R'-R? svi vodik.
The comparison of value of that protein obtained in stage (a) with reference value of that protein for the same biological fluid in women carrying chromosomically normal fetuses. 
PO2743) viša od kvantitativne vrijednosti tog proteina u istoj biološkoj tekućini žena koje nose kromosomski normalne fetuse.
4 shows a diagram of the operation of the device shown in FIGS. 
Slika 4 - prikazuje shemu rada uređaja koji je prikazan na slikama 1,213;
The composition of claim 14, further comprising an immunosuppressive or anti-inflammatory agent. A host cell comprising: 
Smjesa iz zahtjeva 14, naznačena time, što sadrži još i imunosupresivno ili antiupalnog sredstvo.
Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive. 
Formulacije pogodne za transdermalnu primjenu može se prezentirati kao diskretne flastere i mogu biti lipofilne emulzije ili puferirane vodene otopine, otopljene i/ili dispergirane u polimeru 1li ljepilu.
Nucleic acid comprising a nucleic acid sequence encoding the antibody heavy chain or antibody light chain of any one of claims 1 to 7, wherein the nucleic acid is preferably comprised in a vector. 
Nukleinska kiselina koja sadrži sekvencu nukleinske kiseline koja kodira teški lanac antitijela i sekvencu nukleinske kiseline koja kodira laki lanac antitijela kao što je definiran u bilo kojem od patentnih zahtjeva 1 do 6, pri čemu je nukleinska kiselina poželjno sadržana u vektoru.
In some embodiments, the methods of the invention comprise administering at least one compound of Formula I or Formula II to a subject, such as a human, as a preventative measure against cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). 
> Farmaceutski sastav, naznačen time, da se upotrebljava u smanjivanju IL-6 iii VCAM-1 za liječenje raka ili bolesti odabrane od artritisa, astme, dermatitisa, psorijaze, cistične fibroze, kasnije 1 kronično odbacivanje čvrstog organa nakon transplantacije, multiple skleroze, sistemske lupus eritematoze, upalne bolesti crijeva, očne upale, uveitisa, rinitisa, kronične opstrukcijske plućne bolesti (COPD), glomerulonefritisa, Gravesove bolesti, gastrointestinalnih alergija 1 konjunktivitisa kod pojedinca, pri čemu sastav obuhvaća terapeutski učinkovitu količinu najmanje jednog spoja formule II:
For example, but not limited to, congestive heart failure, type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, syndrome X, retinopathy, nephropathy and neuropathy. 
Pripravak u skladu s bilo kojim zahtjevom 1 do 31, 33, 35, 37, 40, 42, 45 i 47, naznačen time, da se koristi u postupku liječenja dijabetesa tip I, dijabetesa tip Il, neodgovarajuće tolerancije glukoze, inzulinske rezistencije, hiperglikemije, hiperlipidemije, hipertrigliceridemije, hiperholesterolemije, dislipidemije ili sindroma X.
Further purification of the solid by recrystallisation from IPA/water (1:3) affords the titled product. 
Naslovni proizvod se dobije daljnjim čišćenjem krute tvari prekristalizacijom iz IPA/vode (1:3).
The nitric ester of Saquinavir according to claim 1 of formula I its non toxic salts, solvates, polymorphic or/and crystalline forms. 
Ester sakvinavira s dušičnom kiselinom u skladu s patentnim zahtjevom 1, naznačen time što ima formulu I [image], njegove netoksične soli, solvati, polimorfni ili/i kristalni oblici.
The method of claim 1, 4-5 and 7 wherein the plurality of neutral atom beam injectors are oriented with an injection path tangential to the FRC with a target trapping zone within separatrix (451) of the FRC. 
. Sustav prema zahtjevu 1, 4 do 5 i 7, naznačen time, da je mnoštvo neutralnih injektora atomskih zraka
The therapeutic hosiery item according to claim 1 or 9, characterized in that the count of said further yarn (1b) that composes said first rows of knitting (1) is comprised between 8.89 and 166.67 dtex. 
Terapeutska čarapa prema zahtjevu 1 ili 9, naznačena time, da se broj spomenutog daljnjeg konca (1b), koji tvori spomenute neparne redove pletiva (1), nalazi između 8,89 i 166,67 deteksa.
A combination according to claim 3, wherein the long-acting B2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. A combination according to claim 4 wherein the long-acting B2 agonist is formoterol fumarate. 
Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine cilomilast, roflumilast, denbufilin i tetomilast, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
or a pharmaceutically acceptable salt thereof, under suitable conditions to form a compound of formula (4): 
H o ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (4):
A compound of Formula (I) according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R8 and R9 taken together with nitrogen to which they are attached form a C5-7 membered saturated non-aromatic heterocyclic ring. 
Spoj Formule (I) u skladu s bilo kojim od patentnih zahtjeva 1-5, ili njegova farmaceutski prihvatljiva sol, naznačen time što R* i R*, uzeti zajedno s dušikom na kojeg su vezani, tvore Cs.7-eročlani zasićen nearomatski heterociklički prsten.
The uplink synchronous status is sustained until the timer expires. According to one embodiment of the present disclosure, a mobile station device transmits a random access preamble to a base station device and resets a timer managing an uplink synchronous status based on reception of the synchronization timing deviation information included in a random access response that the base station device transmits in response to the transmitted random access preamble, wherein, in the uplink synchronous status, the mobile station device does not perform to reset the timer based on reception of synchronization timing deviation information included in a random access response which is a response to a random access preamble whose preamble ID is randomly selected by the mobile station device. 
Uređaj mobilne stanice (50) prema zahtjevu 1, naznačen time da je uređaj mobilne stanice (50) nadalje prilagođen da upravlja sinkronim statusom uzlazne veze korištenjem vremenskog brojača tako da se sinkroni status uzlazne veze održava sve dok istekne vremenski brojač nakon što se vremenski brojač resetira, te pri čemu korak odbacivanja sadrži, u sinkronom statusu uzlazne veze, ne resetiranje vremenskog brojača na osnovi informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02).
conjugating a cytotoxic agent to the cell-binding agents having linkers bound thereto in the purified first mixture by reacting the cell-binding agents having linkers bound thereto with a cytotoxic agent in a solution having a pH of about 6.5 to prepare a second mixture comprising (i) cell-binding agent chemically coupled through the linker to the cytotoxic agent, (ii) free cytotoxic agent, and (iii) reaction by-products, and 
(c) konjugacije maitanzinoida sa antitijelima koja imaju za sebe vezane linkere u pročišćenoj prvoj smjesi putem reakcije antitijela koja imaju za sebe vezane linkere sa maitanzinoidom u otopini koja ima pH od 4 do 9 da bi se pripremila druga smjesa koja sadrži (i) antitijelo kemijski spojeno preko linkera za maitanzinoid, (1i) slobodan maitanzinoid i (iii) sporedne proizvode reakcije, 1
The compound of Claim 1 selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1 izabran iz grupe koju čine:
the connecting lever is formed as one of a punched part, a bent wire part and clip. 
poluga za spajanje (8) je oblikovana kao bušeni dio ili kao savijeni dio žice ili spojnica.
wherein Ra and Rb independently represent, at each occurrence, hydrogen, or a hydrocarbon group comprising a straight chained, branched or cyclic group each containing up to 18 carbon atoms, or a heterocyclic group containing up to 18 carbon atoms and at least one heteroatom; and; or a pharmaceutically acceptable solvate or, more particularly, salt thereof; for use in the treatment of osteoporosis and/or osteopenia. 
[image] gdje Ra i Rb nezavisno predstavljaju, pri svakom pojavljivanju, vodik, ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, ili heterocikličnu grupu koja sadrži do 18 atoma ugljika i barem jedan heteroatom; i n je 0, 1, 2, 3 ili 4; ili farmaceutski prihvatljiv solvat ili, pobliže, njenu sol; za uporabu u liječenju osteoporoze i/ili osteopenije.
The container might be placed for tapping for elongated periods, e.g. two weeks. 
Spremnik se može postaviti za točenje kroz dulji period, npr. dva tjedna.
reacting compound 102 with POCl3 to produce Compound 103 
reakcije Spoja 102 s POCl3 kako bi se dobilo Spoj 103;